In this study, hub genes, KCNMB1, AGPAT4, SVEP1, ADARB1, DCAF5, NRP1, PDIA6, AHI1, ANO6, VPS26A, DNAJC10, TMEM106B, ETF1, GCC2, FNBP1, and GOLGA8B, which might be used as targets and biomarkers for treating GBM were selected. This evidence concerns the gene DCAF5 and glioblastoma.